Edoardo

[Edoardo @EdoGal89]

Is this for real?! Thanks to all my coauthors, collaborators and friends @BecherLab, and @NatureMedicine of course. Another step closer to the understanding of #MultipleSclerosis, aiming to provide a better care for these patients. https://t.co/pR08C9FYm0

[Edoardo @EdoGal89]

@MikeRecher Fact: low IgG + a handshake that won't let go? CVID isn't necessarily the first differential to consider!
In DM1, IgG deficiency is common, and likely reflects increased catabolism rather than failed production. A diagnosis not to miss!
@UniSpitalBasel @UniBasel @Uniklinik_Fr

[Edoardo @EdoGal89]

Neurology meets immunology 🧠🤝🛡️
When the patient is so impressed of the diagnosis, that just can't let go of your hand. Literally: grip myotonia 😉

Fantastic interdisciplinary work led by the always brilliant @MikeRecher
Big thanks to the co-authors and patients!

[Journal of Human Immunity @jhumimmunity]

Galli, Recher et al. describe two patients with hypogammaglobulinemia associated with #MyotonicDystrophy type 1 (DM1), a rare and underdiagnosed monogenic neuromuscular disorder and provide clues to aid clinical immunologists in making a correct diagnosis. https://t.co/nTUxfzOP3V

[Saligrama lab_WUSTL @SaligramaLab]

#Happy to #share this #collaborative paper @PNASNews A tonsil organoid model reveals #EBV–infected germinal center B cell states during primary infection | PNAS https://t.co/lyWH8SBCZY

[Journal of Human Immunity @jhumimmunity]

Meyer, Loureiro, Recher et al. (University of Basel) identify a TCR γδ cell-specific STAT5 gain of function mutation in patients with a unique chronic human immune dysregulation that alters the T cell differentiation program and is specifically druggable. https://t.co/mwRCkOJ4b8

[Journal of Human Immunity @jhumimmunity]

In a new review on DADA2, @IsabelleMeyts et al. cover the full spectrum of disease (vasculitis, bone marrow failure, immunodeficiency), TNF inhibitors, stem cell transplant, & #genetherapy on the horizon, the concept that a single variant can cause disease https://t.co/3I0ku6T9nz

[Ruslan Rust @rust_ruslan]

New preprint: mass cytometry across 351 blood + CSF samples, two cohorts, full AD continuum.

Peripheral immune signatures (pAkt in naïve T killer cells, pPLCγ2 in granulocytes) emerge in preclinical AD, before plasma ptau217, CSF ptau181, and DCE-MRI BBB disruption. Not seen in FTLD or MS.

I guess this suggests that immune changes are among the earliest detectable events in AD. Might have implications for early biomarkers.

https://t.co/obFjpMhbKc

[Edoardo @EdoGal89]

@jsabatino37 @NatImmunol Very nice work and smart approach 👍 Congratulations!

[Caleb Lareau @CalebLareau]

It’s been awesome to see the interest in our paper on EBV DNA persistence.

Many folks have asked about multiple sclerosis in this context, and I thought I’d take a moment to share some thoughts that were too speculative and/or space-constrained for the final manuscript. 1/n

[NEJM @NEJM]

Original Article: Common Diseases in Clinical Cohorts — Not Always What They Seem https://t.co/PBk8feriL4

Editorial: A Rare-in-Common Paradigm for Precision Genomic Medicine https://t.co/wKXF0QInBB

#Genetics

[ECTRIMS @ECTRIMS]

Don’t miss our post #ECTRIMS2025 abstract webinar happening TODAY at 13:00 CEST - featuring one standout abstract from each track — Clinical, Therapy, Pathogenesis, & Imaging & Non-imaging Biomarkers

👉 Secure your spot: https://t.co/w2UgoA6dzY

Moderators: Stefan Bittner from @UnimedizinMainz, and Edoardo Galli from @Universitt92054

Speakers: Gloria Dalla Costa from @Harvard, Andrea Landwehr from Universitätsklinikum Münster, Izanne Roos from @TheRMH, and Yasemin Şimşek from Izmir University of Economics Medical Point Hospital.

#MSResearch #Neurology

[ECTRIMS @ECTRIMS]

📢 Breaking news: The 2024 revised #McDonaldCriteria have been published in @TheLancetNeuro. Explore the latest evidence shaping #MSDiagnosis. Published by the International Advisory Committee for Clinical Trials in #MS.
👉 https://t.co/8V2lWodMm2
@mssociety #MSResearch #IACCTMS

[Edoardo @EdoGal89]

@gallinari8888 Bomber hai dimenticato settembre

[Edoardo @EdoGal89]

Brilliant approach with terrific implications in clinical MS. Chapeau

[Heinz Wiendl @hwiendl]

🚨 Paradigm shift in #MultipleSclerosis 🚨
New study in Nature Medicine shows MS is not fixed subtypes but a dynamic continuum of states across 4 dimensions: disability, brain damage, relapses & silent inflammation.

📖 Read: https://t.co/MYvAAI6AiV
#MS #Neurology #AI

[ECTRIMS @ECTRIMS]

Are you a researcher or healthcare professional (HCP) under 40 or in your early career who's attending #ECTRIMS2025 in Barcelona? Join the Young #MS HCP & Researcher Networking Event!
🗓️ 24 Sep 2025, 18:45-20:30 CEST
📍 NeuroNetwork

Sign up for free 👉 https://t.co/5DpYXGfiK4

[nature @Nature]

Nature research paper: EBV induces CNS homing of B cells attracting inflammatory T cells

https://t.co/iCSDKxjkp7

[ECTRIMS @ECTRIMS]

🎓 Webcasts from our Summer School in Stockholm this June are now available on #myECTRIMS! Gain insights from leading experts on Visual System Evaluation in #MS and Other Demyelinating Diseases. Watch them here: https://t.co/ZZx9ZubXn0
#ECTRIMSNextGen #MultipleSclerosis

[NEJM @NEJM]

In the latest video in our partnership with @DGlaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free: https://t.co/A7Z3do3VF6

[ECTRIMS @ECTRIMS]

📢 Last call! Are you an early career #MS professional looking for guidance and support? Join the #ECTRIMS #Mentorship Programme! #ECTRIMSNextGen
✅ Sign up as a mentee and get matched ➡️ https://t.co/VaTyjH4ahh
Deadline: 30 June.

[Edoardo @EdoGal89]

Long due but incredibly welcome step forward in MS! A major milestone that will massively impact every aspect of how we understand and treat MS, from trial design to targeting specific biological drivers of disease.

Exciting times ahead!

#Neuroimmunology #RC2NB #ECTRIMS

[ECTRIMS @ECTRIMS]

The International Advisory Committee on Clinical Trials in #MS met in May to discuss a topic that could reshape the landscape of MS care and research: the revision of MS course descriptors. Learn why this is an important step forward in #MSResearch: ➡️ https://t.co/zsQB5GY1b9

[ECTRIMS @ECTRIMS]

🧬Why do some people develop MS while others do not? No single genetic variant alone can cause MS. Each one adds incrementally to the overall risk – an effect known as polygenicity. Discover more in our latest Spotlight 👉 https://t.co/hcMYK4NXdH #MS #Genetics